The Filings Report

Kymera Therapeutics, Inc. Common Stock

KYMRNasdaqCIK 1815442Healthcare / Biotechnologyfiscal year ends December29 quarters since 2019

Revenue, Q3 FY2026
$0
−100.0% on Q3 FY2025
Net income
−$132M
−60.6% on Q3 FY2025
Free cash flow
−$78M
−186.6% on Q3 FY2025
Diluted EPS
$-1.32
−40.4% on Q3 FY2025
Revenue, TTM
$102M
trailing four quarters
Net margin, TTM
-341.8%
net income −$349M
Free cash flow, TTM
−$289M
−$288M less $1M capex
Cash and equivalents
$373M
long-term debt —, Sep 30, 2026
Shares, 12-month change
+18.7%
85M shares, Sep 30, 2026
Buybacks, TTM
—
no yield
Dividends, TTM
—
no yield
Market value
$11.2B
at the close, buybacks

Latest quarter Q3 FY2026, filed October 29, 2026. Trailing figures sum the latest four quarters. Market values at the latest close, from a market data vendor.

In Q3 FY2026, the quarter ended September 30, 2026, Kymera Therapeutics, Inc. Common Stock reported revenue of $0, −100.0% on Q3 FY2025, and net loss of $132M (−60.6%). Free cash flow, operating cash flow less capital expenditures, was −$78M (−$78M less $315K). Diluted earnings per share were $-1.32.

Share price

Daily candlesticks from November 11, 2024 to November 6, 2026, with each earnings release marked; a release after the close marks the day it came out, so its reaction is the next candle. See this earnings season for every company’s reaction.

KYMR daily priceSplit-adjusted, US dollars; an earnings release
Nov 6, 2026O $129.41 · H $132.68 · L $126.65 · C $131.73 · +2.82% on the dayOver the range: +115.95%, Nov 7, 2025 to Nov 6, 2026
$52$75$97$120$143Nov 25Jan 26Apr 26Jun 26Aug 26Nov 26

The last 16 quarters

Q4 FY2022 to Q3 FY2026, through the filing of October 29, 2026.

Revenue and net incomeRevenueNet income
−$150M−$100M−$50M$0$50M$100MQ4'22, Revenue: $16MQ4'22, Net income: −$35MQ4'22Q1'23, Revenue: $9MQ1'23, Net income: −$41MQ1'23Q2'23, Revenue: $17MQ2'23, Net income: −$39MQ2'23Q3'23, Revenue: $5MQ3'23, Net income: −$53MQ3'23Q4'23, Revenue: $48MQ4'23, Net income: −$14MQ4'23Q1'24, Revenue: $10MQ1'24, Net income: −$49MQ1'24Q2'24, Revenue: $26MQ2'24, Net income: −$42MQ2'24Q3'24, Revenue: $4MQ3'24, Net income: −$62MQ3'24Q4'24, Revenue: $7MQ4'24, Net income: −$71MQ4'24Q1'25, Revenue: $22MQ1'25, Net income: −$66MQ1'25Q2'25, Revenue: $11MQ2'25, Net income: −$77MQ2'25Q3'25, Revenue: $3MQ3'25, Net income: −$82MQ3'25Q4'25, Revenue: $3MQ4'25, Net income: −$87MQ4'25Q1'26, Revenue: $34MQ1'26, Net income: −$69MQ1'26Q2'26, Revenue: $65MQ2'26, Net income: −$61MQ2'26Q3'26, Revenue: $0Q3'26, Net income: −$132MQ3'26−$150M−$100M−$50M$0$50M$100MQ4'22, Revenue: $16MQ4'22, Net income: −$35MQ4'22Q1'23, Revenue: $9MQ1'23, Net income: −$41MQ1'23Q2'23, Revenue: $17MQ2'23, Net income: −$39MQ2'23Q3'23, Revenue: $5MQ3'23, Net income: −$53MQ3'23Q4'23, Revenue: $48MQ4'23, Net income: −$14MQ4'23Q1'24, Revenue: $10MQ1'24, Net income: −$49MQ1'24Q2'24, Revenue: $26MQ2'24, Net income: −$42MQ2'24Q3'24, Revenue: $4MQ3'24, Net income: −$62MQ3'24Q4'24, Revenue: $7MQ4'24, Net income: −$71MQ4'24Q1'25, Revenue: $22MQ1'25, Net income: −$66MQ1'25Q2'25, Revenue: $11MQ2'25, Net income: −$77MQ2'25Q3'25, Revenue: $3MQ3'25, Net income: −$82MQ3'25Q4'25, Revenue: $3MQ4'25, Net income: −$87MQ4'25Q1'26, Revenue: $34MQ1'26, Net income: −$69MQ1'26Q2'26, Revenue: $65MQ2'26, Net income: −$61MQ2'26Q3'26, Revenue: $0Q3'26, Net income: −$132MQ3'26−$150M−$100M−$50M$0$50M$100MQ4'22, Revenue: $16MQ4'22, Net income: −$35MQ1'23, Revenue: $9MQ1'23, Net income: −$41MQ1'23Q2'23, Revenue: $17MQ2'23, Net income: −$39MQ3'23, Revenue: $5MQ3'23, Net income: −$53MQ3'23Q4'23, Revenue: $48MQ4'23, Net income: −$14MQ1'24, Revenue: $10MQ1'24, Net income: −$49MQ1'24Q2'24, Revenue: $26MQ2'24, Net income: −$42MQ3'24, Revenue: $4MQ3'24, Net income: −$62MQ3'24Q4'24, Revenue: $7MQ4'24, Net income: −$71MQ1'25, Revenue: $22MQ1'25, Net income: −$66MQ1'25Q2'25, Revenue: $11MQ2'25, Net income: −$77MQ3'25, Revenue: $3MQ3'25, Net income: −$82MQ3'25Q4'25, Revenue: $3MQ4'25, Net income: −$87MQ1'26, Revenue: $34MQ1'26, Net income: −$69MQ1'26Q2'26, Revenue: $65MQ2'26, Net income: −$61MQ3'26, Revenue: $0Q3'26, Net income: −$132MQ3'26

Net income losses drawn in red.

Free cash flow
−$100M−$75M−$50M−$25M$0$25MQ4'22, Free cash flow: −$40MQ4'22Q1'23, Free cash flow: −$48MQ1'23Q2'23, Free cash flow: −$46MQ2'23Q3'23, Free cash flow: −$40MQ3'23Q4'23, Free cash flow: −$4MQ4'23Q1'24, Free cash flow: −$47MQ1'24Q2'24, Free cash flow: −$48MQ2'24Q3'24, Free cash flow: −$50MQ3'24Q4'24, Free cash flow: −$63MQ4'24Q1'25, Free cash flow: −$80MQ1'25Q2'25, Free cash flow: −$61MQ2'25Q3'25, Free cash flow: −$27MQ3'25Q4'25, Free cash flow: −$67MQ4'25Q1'26, Free cash flow: −$89MQ1'26Q2'26, Free cash flow: −$55MQ2'26Q3'26, Free cash flow: −$78MQ3'26−$100M−$75M−$50M−$25M$0$25MQ4'22, Free cash flow: −$40MQ4'22Q1'23, Free cash flow: −$48MQ1'23Q2'23, Free cash flow: −$46MQ2'23Q3'23, Free cash flow: −$40MQ3'23Q4'23, Free cash flow: −$4MQ4'23Q1'24, Free cash flow: −$47MQ1'24Q2'24, Free cash flow: −$48MQ2'24Q3'24, Free cash flow: −$50MQ3'24Q4'24, Free cash flow: −$63MQ4'24Q1'25, Free cash flow: −$80MQ1'25Q2'25, Free cash flow: −$61MQ2'25Q3'25, Free cash flow: −$27MQ3'25Q4'25, Free cash flow: −$67MQ4'25Q1'26, Free cash flow: −$89MQ1'26Q2'26, Free cash flow: −$55MQ2'26Q3'26, Free cash flow: −$78MQ3'26−$100M−$75M−$50M−$25M$0$25MQ4'22, Free cash flow: −$40MQ1'23, Free cash flow: −$48MQ1'23Q2'23, Free cash flow: −$46MQ3'23, Free cash flow: −$40MQ3'23Q4'23, Free cash flow: −$4MQ1'24, Free cash flow: −$47MQ1'24Q2'24, Free cash flow: −$48MQ3'24, Free cash flow: −$50MQ3'24Q4'24, Free cash flow: −$63MQ1'25, Free cash flow: −$80MQ1'25Q2'25, Free cash flow: −$61MQ3'25, Free cash flow: −$27MQ3'25Q4'25, Free cash flow: −$67MQ1'26, Free cash flow: −$89MQ1'26Q2'26, Free cash flow: −$55MQ3'26, Free cash flow: −$78MQ3'26

Operating cash flow less capital expenditures; negative quarters in red.

Cash and equivalents against long-term debtCash and equivalentsLong-term debt
$0$100M$200M$300M$400MQ4'22, Cash and equivalents: $68MQ4'22Q1'23, Cash and equivalents: $50MQ1'23Q2'23, Cash and equivalents: $52MQ2'23Q3'23, Cash and equivalents: $81MQ3'23Q4'23, Cash and equivalents: $110MQ4'23Q1'24, Cash and equivalents: $94MQ1'24Q2'24, Cash and equivalents: $68MQ2'24Q3'24, Cash and equivalents: $111MQ3'24Q4'24, Cash and equivalents: $120MQ4'24Q1'25, Cash and equivalents: $90MQ1'25Q2'25, Cash and equivalents: $336MQ2'25Q3'25, Cash and equivalents: $113MQ3'25Q4'25, Cash and equivalents: $357MQ4'25Q1'26, Cash and equivalents: $144MQ1'26Q2'26, Cash and equivalents: $124MQ2'26Q3'26, Cash and equivalents: $373MQ3'26$0$100M$200M$300M$400MQ4'22, Cash and equivalents: $68MQ4'22Q1'23, Cash and equivalents: $50MQ1'23Q2'23, Cash and equivalents: $52MQ2'23Q3'23, Cash and equivalents: $81MQ3'23Q4'23, Cash and equivalents: $110MQ4'23Q1'24, Cash and equivalents: $94MQ1'24Q2'24, Cash and equivalents: $68MQ2'24Q3'24, Cash and equivalents: $111MQ3'24Q4'24, Cash and equivalents: $120MQ4'24Q1'25, Cash and equivalents: $90MQ1'25Q2'25, Cash and equivalents: $336MQ2'25Q3'25, Cash and equivalents: $113MQ3'25Q4'25, Cash and equivalents: $357MQ4'25Q1'26, Cash and equivalents: $144MQ1'26Q2'26, Cash and equivalents: $124MQ2'26Q3'26, Cash and equivalents: $373MQ3'26$0$100M$200M$300M$400MQ4'22, Cash and equivalents: $68MQ1'23, Cash and equivalents: $50MQ1'23Q2'23, Cash and equivalents: $52MQ3'23, Cash and equivalents: $81MQ3'23Q4'23, Cash and equivalents: $110MQ1'24, Cash and equivalents: $94MQ1'24Q2'24, Cash and equivalents: $68MQ3'24, Cash and equivalents: $111MQ3'24Q4'24, Cash and equivalents: $120MQ1'25, Cash and equivalents: $90MQ1'25Q2'25, Cash and equivalents: $336MQ3'25, Cash and equivalents: $113MQ3'25Q4'25, Cash and equivalents: $357MQ1'26, Cash and equivalents: $144MQ1'26Q2'26, Cash and equivalents: $124MQ3'26, Cash and equivalents: $373MQ3'26

Positions at each quarter end, as filed; short-term investments are not included.

Income statement

Last eight quarters, newest first, through Q3 FY2026 filed October 29, 2026.

Kymera Therapeutics, Inc. Common Stock income statement, quarterly
Millions of dollarsQ3 FY2026ended Sep 30, 2026filed Oct 29, 2026Q2 FY2026ended Jun 30, 2026filed Aug 5, 2026Q1 FY2026ended Mar 31, 2026filed Apr 30, 2026Q4 FY2025ended Dec 31, 2025filed Feb 26, 2026Q3 FY2025ended Sep 30, 2025filed Nov 4, 2025Q2 FY2025ended Jun 30, 2025filed Aug 11, 2025Q1 FY2025ended Mar 31, 2025filed May 9, 2025Q4 FY2024ended Dec 31, 2024filed Feb 27, 2025YoYQ3 FY2026vs Q3 FY2025
Revenue065343311227−100.0%
Cost of revenue065343311227−100.0%
Gross profit—————————
Research and development129119988474788072+73.4%
Selling, general and administrative1921201717181616+8.0%
Operating income(147)(76)(84)(98)(93)(85)(74)(81)−59.1%
Other income (expense)15141511108910+47.2%
Pretax income—————————
Income tax—————————
Net income(132)(61)(69)(87)(82)(77)(66)(71)−60.6%
Diluted EPS ($)(1.32)(0.62)(0.71)—(0.94)(0.95)(0.82)—−40.4%
Diluted shares (millions)1009898—878080——

Fourth quarters are the fiscal year less the first nine months when the filer reports no discrete fourth quarter, and are marked. Diluted EPS is never derived, so a derived quarter shows none. Italic figures are derived.

Balance sheet

Last eight quarters, newest first, through Q3 FY2026 filed October 29, 2026.

Kymera Therapeutics, Inc. Common Stock balance sheet, quarterly
Millions of dollarsQ3 FY2026ended Sep 30, 2026filed Oct 29, 2026Q2 FY2026ended Jun 30, 2026filed Aug 5, 2026Q1 FY2026ended Mar 31, 2026filed Apr 30, 2026Q4 FY2025ended Dec 31, 2025filed Feb 26, 2026Q3 FY2025ended Sep 30, 2025filed Nov 4, 2025Q2 FY2025ended Jun 30, 2025filed Aug 11, 2025Q1 FY2025ended Mar 31, 2025filed May 9, 2025Q4 FY2024ended Dec 31, 2024filed Feb 27, 2025YoYQ3 FY2026vs Q3 FY2025
Cash and equivalents37312414435711333690120+230.6%
Short-term investments598567507491393330373368+52.2%
Total current assets999737677871528728501510+89.0%
Total assets1,7671,6451,6691,7431,1021,131918978+60.4%
Total current liabilities9071638372885968+25.4%
Long-term debt—————————
Total liabilities153136129163156160132142−2.0%
Stockholders’ equity1,6151,5091,5401,580946971786836+70.6%
Shares outstanding (millions)8583828272716565—

Positions at each period end. Nothing on this statement is derived. Long-term debt is the filed noncurrent line only; no total-debt composite is constructed across filers. Italic figures are derived.

Cash flow statement

Last eight quarters, newest first, through Q3 FY2026 filed October 29, 2026.

Kymera Therapeutics, Inc. Common Stock cash flow statement, quarterly
Millions of dollarsQ3 FY2026ended Sep 30, 2026filed Oct 29, 2026Q2 FY2026ended Jun 30, 2026filed Aug 5, 2026Q1 FY2026ended Mar 31, 2026filed Apr 30, 2026Q4 FY2025ended Dec 31, 2025filed Feb 26, 2026Q3 FY2025ended Sep 30, 2025filed Nov 4, 2025Q2 FY2025ended Jun 30, 2025filed Aug 11, 2025Q1 FY2025ended Mar 31, 2025filed May 9, 2025Q4 FY2024ended Dec 31, 2024filed Feb 27, 2025YoYQ3 FY2026vs Q3 FY2025
Operating cash flow(78)(54)(89)(67)(27)(60)(79)(62)−187.4%
Capital expenditures00000101+74.0%
Free cash flow (CFO − capex)(78)(55)(89)(67)(27)(61)(80)(63)−186.6%
Depreciation and amortization22222222−5.9%
Share repurchases—————————
Dividends paid—————————

10-Qs file cash flows as year-to-date totals, so quarterly figures are differenced from consecutive filings and marked. Free cash flow is operating cash flow less capital expenditures, computed from the two filed lines. Italic figures are derived.

Annual statements

Every fiscal year filed, newest first, through FY2025 filed February 26, 2026.

Income statement

Kymera Therapeutics, Inc. Common Stock income statement, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 26, 2026FY2024ended Dec 31, 2024filed Feb 27, 2025FY2023ended Dec 31, 2023filed Feb 22, 2024FY2022ended Dec 31, 2022filed Feb 23, 2023FY2021ended Dec 31, 2021filed Feb 24, 2022FY2020ended Dec 31, 2020filed Mar 11, 2021FY2019ended Dec 31, 2019filed Nov 5, 2020
Revenue3947794773343
Cost of revenue39477947———
Gross profit———————
Research and development3172401891641376237
Selling, general and administrative6864554436188
Operating income(349)(262)(166)(161)(101)(46)(42)
Other income (expense)3838196011
Pretax income(311)——————
Income tax0——0000
Net income(311)(224)(147)(155)(100)(46)(41)
Diluted EPS ($)(3.69)(2.98)(2.52)(2.87)(2.09)(3.15)—
Diluted shares (millions)847558544817—

Balance sheet

Kymera Therapeutics, Inc. Common Stock balance sheet, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 26, 2026FY2024ended Dec 31, 2024filed Feb 27, 2025FY2023ended Dec 31, 2023filed Feb 22, 2024FY2022ended Dec 31, 2022filed Feb 23, 2023FY2021ended Dec 31, 2021filed Feb 24, 2022FY2020ended Dec 31, 2020filed Mar 11, 2021FY2019ended Dec 31, 2019filed Nov 5, 2020
Cash and equivalents35712011068483176
Short-term investments49136826533939426516
Total current assets87151040541945130293
Total assets1,743978576603606487117
Total current liabilities836886719311135
Long-term debt———————
Total liabilities16314218111314620382
Stockholders’ equity1,580836395490460284(74)
Shares outstanding (millions)826561555245—

Cash flow statement

Kymera Therapeutics, Inc. Common Stock cash flow statement, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 26, 2026FY2024ended Dec 31, 2024filed Feb 27, 2025FY2023ended Dec 31, 2023filed Feb 22, 2024FY2022ended Dec 31, 2022filed Feb 23, 2023FY2021ended Dec 31, 2021filed Feb 24, 2022FY2020ended Dec 31, 2020filed Mar 11, 2021FY2019ended Dec 31, 2019filed Nov 5, 2020
Operating cash flow(233)(195)(103)(153)(129)8818
Capital expenditures113343291
Free cash flow (CFO − capex)(234)(207)(137)(156)(131)7917
Depreciation and amortization8743221
Share repurchases———————
Dividends paid———————

Insider activity

Form 4 filings by officers, directors and 10% owners, November 9, 2024 to November 9, 2026. Only open-market purchases and sales count as buys and sells; awards, exercises, tax withholding and gifts are listed in grey and never counted.

Bought, three months
$0
0 purchases by 0 insiders; officers and directors $0
Sold, three months
$4M
9 sales by 2 insiders; officers and directors $4M
Bought, twelve months
$172M
2 purchases by 1 insider; officers and directors $172M
Sold, twelve months
$473M
274 sales by 11 insiders; officers and directors $473M

The last 25 transactions

TradedInsiderRoleTransactionSharesPriceValueHeld afterFiled
Oct 1, 2026Mainolfi NelloChief Executive Officer, Directoroption exercise30,000$2.08$62K696,568Oct 1, 2026
Oct 1, 2026Mainolfi NelloChief Executive Officer, Directoropen-market sale10b5-13,525$111.44$393K693,043Oct 1, 2026
Oct 1, 2026Mainolfi NelloChief Executive Officer, Directoropen-market sale10b5-15,506$112.42$619K687,537Oct 1, 2026
Oct 1, 2026Mainolfi NelloChief Executive Officer, Directoropen-market sale10b5-14,876$113.24$552K682,661Oct 1, 2026
Oct 1, 2026Mainolfi NelloChief Executive Officer, Directoropen-market sale10b5-17,601$114.43$870K675,060Oct 1, 2026
Oct 1, 2026Mainolfi NelloChief Executive Officer, Directoropen-market sale10b5-18,230$115.40$950K666,830Oct 1, 2026
Oct 1, 2026Mainolfi NelloChief Executive Officer, Directoropen-market sale10b5-1262$116.12$30K666,568Oct 1, 2026
Sep 4, 2026Adams BrianChief Legal Officeropen-market sale1,209$115.55$140K55,416Sep 4, 2026
Sep 4, 2026Adams BrianChief Legal Officeropen-market sale3,025$116.81$353K52,391Sep 4, 2026
Sep 4, 2026Adams BrianChief Legal Officeropen-market sale2,137$117.57$251K50,254Sep 4, 2026
Jul 27, 2026Rooney TerenceChief Medical Officeraward38,000$0.00—38,000Jul 27, 2026
Jul 7, 2026Mainolfi NelloChief Executive Officer, Directoroption exercise50,000$2.08$104K716,568Jul 7, 2026
Jul 7, 2026Mainolfi NelloChief Executive Officer, Directoropen-market sale10b5-150,000$119.00$6M666,568Jul 7, 2026
Jul 1, 2026Goodman NoahChief Business Officeropen-market sale10b5-13,389$114.29$387K47,179Jul 2, 2026
Jul 1, 2026Mainolfi NelloChief Executive Officer, Directoroption exercise80,000$2.08$166K746,568Jul 2, 2026
Jul 1, 2026Mainolfi NelloChief Executive Officer, Directoropen-market sale10b5-11,883$112.80$212K744,685Jul 2, 2026
Jul 1, 2026Mainolfi NelloChief Executive Officer, Directoropen-market sale10b5-16,626$113.98$755K738,059Jul 2, 2026
Jul 1, 2026Mainolfi NelloChief Executive Officer, Directoropen-market sale10b5-124,105$114.96$3M713,954Jul 2, 2026
Jul 1, 2026Mainolfi NelloChief Executive Officer, Directoropen-market sale10b5-144,050$115.69$5M669,904Jul 2, 2026
Jul 1, 2026Mainolfi NelloChief Executive Officer, Directoropen-market sale10b5-13,336$116.56$389K666,568Jul 2, 2026
Jun 30, 2026Jacobs Bruce N.Chief Financial Officeroption exercise61,378$5.33$327K321,992Jul 2, 2026
Jun 30, 2026Jacobs Bruce N.Chief Financial Officeropen-market sale10b5-11,500$110.54$166K320,492Jul 2, 2026
Jun 30, 2026Jacobs Bruce N.Chief Financial Officeropen-market sale10b5-11,700$111.57$190K318,792Jul 2, 2026
Jun 30, 2026Jacobs Bruce N.Chief Financial Officeropen-market sale10b5-11,100$112.79$124K317,692Jul 2, 2026
Jun 30, 2026Jacobs Bruce N.Chief Financial Officeropen-market sale10b5-14,110$114.19$469K313,582Jul 2, 2026

Full insider history for Kymera Therapeutics, Inc. Common Stock, or insider activity across all companies. A record of filings, not a recommendation.

Tracked funds holding it

1 of the tracked managers held KYMR in their latest 13F filing, through August 14, 2026. Weight is the share of the fund’s reported portfolio. How the funds have traded KYMR by quarter.

FundManagerQuarterValueSharesWeightMove
Baron Capital GroupRon BaronQ2 2026$2M20,0000.00%held

Sources

Fiscal year ends in month 12; periods are labeled with the issuer's own fiscal calendar. Values are as most recently filed (restatements apply; per-share values are on current split basis per the connector's split table, flagged in adjusted). Flow items flagged in `derived` were computed (Q4 = FY − nine months; quarterly cash flow differenced from year-to-date filings) rather than read from a filing. `reconciliation.repaired` lists periods where a full-year figure was filed in a quarter slot: that row was dropped and the quarter rebuilt from the annual figure. `reconciliation.quarantined` lists periods where four filed quarters do not sum to the filed year — those quarterly values are withheld, so a blank there is a withholding rather than an absence of reporting.

Filer
KYMERA THERAPEUTICS, INC., CIK 1815442 on EDGAR
Extract generated
November 8, 2026
Withheld
none
Repaired
none
XBRL concepts behind each line

Income statement

Revenue: RevenueFromContractWithCustomerExcludingAssessedTax
Cost of revenue: CostOfRevenue
Gross profit: not filed
Research and development: ResearchAndDevelopmentExpense
Selling, general and administrative: GeneralAndAdministrativeExpense
Operating income: OperatingIncomeLoss
Other income (expense): OtherNonoperatingIncomeExpense
Pretax income: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
Income tax: IncomeTaxExpenseBenefit
Net income: NetIncomeLoss
Diluted EPS ($): EarningsPerShareDiluted
Diluted shares (millions): WeightedAverageNumberOfDilutedSharesOutstanding

Balance sheet

Cash and equivalents: CashAndCashEquivalentsAtCarryingValue
Short-term investments: AvailableForSaleSecuritiesDebtSecuritiesCurrent
Total current assets: AssetsCurrent
Total assets: Assets
Total current liabilities: LiabilitiesCurrent
Long-term debt: not filed
Total liabilities: Liabilities
Stockholders’ equity: StockholdersEquity
Shares outstanding (millions): dei:EntityCommonStockSharesOutstanding

Cash flow statement

Operating cash flow: NetCashProvidedByUsedInOperatingActivities
Capital expenditures: PaymentsToAcquirePropertyPlantAndEquipment
Free cash flow (CFO − capex): not filed
Depreciation and amortization: DepreciationDepletionAndAmortization
Share repurchases: not filed
Dividends paid: not filed

The data

The statements on this page as files, generated November 8, 2026.

JSON file
/data/financials/KYMR.json